Evidence map›Paper›PMID 31965751›Full record

ArticleCancer medicine2020

Race, tumor location, and disease progression among low-risk prostate cancer patients.

Justin G Mygatt, Jennifer Cullen, Samantha A Streicher, Huai-Ching Kuo, Yongmei Chen, Denise Young, William Gesztes, Grant Williams, Galen Conti, Christopher Porter and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Justin G MygattUrology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Jennifer CullenCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID 0000-0002-2123-416X
Samantha A StreicherCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID 0000-0002-0455-2131
Huai-Ching KuoCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Yongmei ChenCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID 0000-0003-1461-4890
Denise YoungCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
William GesztesJoint Pathology Center, Silver Spring, MD, USA.
Grant WilliamsJoint Pathology Center, Silver Spring, MD, USA.
Galen ContiCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Christopher PorterCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Sean P StroupCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Kevin R RiceUrology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Inger L RosnerUrology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Allen BurkeJoint Pathology Center, Silver Spring, MD, USA.
Isabell SesterhennJoint Pathology Center, Silver Spring, MD, USA.
Henry M. Jackson Foundation · USUniformed Services University of the Health Sciences · USWalter Reed National Military Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between race, prostate tumor location, and BCR-free survival is inconclusive. This study examined the independent and joint roles of patient race and tumor location on biochemical recurrence-free (BCR) survival.

methodsA retrospective cohort study was conducted among men with newly diagnosed, biopsy-confirmed, NCCN-defined low risk CaP who underwent radical prostatectomy (RP) at the Walter Reed National Military Medical Center from 1996 to 2008. BCR-free survival was modeled using Kaplan-Meier estimation curves and multivariable Cox proportional hazards (PH) analyses.

resultsThere were 539 eligible patients with low-risk CaP (25% African American, AA; 75% Caucasian American, CA). Median age at CaP diagnosis and post-RP follow-up time was 59.2 and 8.1 years, respectively. Kaplan-Meier analyses showed no significant association between race (P = .52) or predominant tumor location (P = .98) on BCR-free survival. In Cox PH multivariable analysis, neither race (HR = 1.18; 95% CI = 0.68-2.02; P = .56) nor predominant tumor location (HR = 1.13; 95% CI = 0.59-2.15; P = .71) was an independent predictor of BCR-free survival.

conclusionsNeither race nor predominant tumor location was associated with adverse oncologic outcome.

Indexed as

ProstatectomyAdultAgedBiopsyBlack or African AmericanDisease-Free SurvivalDisease ProgressionFollow-Up StudiesHumansKallikreinsKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsKallikreinsKLK3 protein, humanProstate-Specific Antigengeneral surgeryprostatic neoplasmsrace factorsrisk

Identifiers

PMID31965751
PMCPMC7064097
OpenAlexW3002225818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.